---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-014473"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2025-01-28T23:59:59+00:00"
generated_at: "2026-05-27T08:18:26.719202+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeuroPace issues 2025 revenue guidance $92M-$96M; 3-year CAGR target 20%+

## Summary
- 2025 revenue guidance $92M-$96M (15.5%-20.5% YoY growth); gross margin 73%-75%; total OpEx $92M-$95M.
- Three-year targets: 20%+ revenue CAGR, indication expansion to IGE/pediatric, AI tools, and cash flow breakeven.
- Post-approval trial: 82% median seizure reduction at 36 months (n=255); 42.5% seizure-free ≥6 months; 22% ≥1 year.
- NAUTILUS trial (IGE): 87 patients implanted; 1-yr follow-up due by March 2025; data lock Q2 2025; FDA submission H2 2025.
- Plans to release first AI-powered electrographic seizure classifier tool within RNS System PDMS in 2025.

## SEC filing metadata
- accession: 0001193125-25-014473
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2025-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000119312525014473/0001193125-25-014473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000119312525014473/d877194d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-014473
- JSON: https://secwatch.observer/filing/0001193125-25-014473.json
- Plain text: https://secwatch.observer/filing/0001193125-25-014473.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.